326 related articles for article (PubMed ID: 21726264)
21. [Research for cell therapy by induced pluripotent stem cell].
Sakurai H; Yamanaka S
Nihon Rinsho; 2011 Dec; 69(12):2114-8. PubMed ID: 22242307
[TBL] [Abstract][Full Text] [Related]
22. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
23. Microbicide research in developing countries: have we given the ethical concerns due consideration?
Moodley K
BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
[TBL] [Abstract][Full Text] [Related]
24. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
[TBL] [Abstract][Full Text] [Related]
25. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
[TBL] [Abstract][Full Text] [Related]
26. Risk of tumorigenesis in first-in-human trials of embryonic stem cell neural derivatives: Ethics in the face of long-term uncertainty.
Hess PG
Account Res; 2009 Jul; 16(4):175-98. PubMed ID: 20183160
[TBL] [Abstract][Full Text] [Related]
27. Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease.
Lo B; Parham L
J Law Med Ethics; 2010; 38(2):257-66. PubMed ID: 20579249
[TBL] [Abstract][Full Text] [Related]
28. Science and society: a stem cell technology model.
Kiatpongsan S
J Med Assoc Thai; 2008 Feb; 91(2):268-71. PubMed ID: 18389995
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of induced pluripotent stem cells into functional oligodendrocytes.
Czepiel M; Balasubramaniyan V; Schaafsma W; Stancic M; Mikkers H; Huisman C; Boddeke E; Copray S
Glia; 2011 Jun; 59(6):882-92. PubMed ID: 21438010
[TBL] [Abstract][Full Text] [Related]
30. [Induced pluripotent stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects].
Nishiyama T; Takeda S
Brain Nerve; 2012 Jan; 64(1):39-46. PubMed ID: 22223500
[TBL] [Abstract][Full Text] [Related]
31. Human cord blood applications in cell therapy: looking back and look ahead.
Zhou H; Chang S; Rao M
Expert Opin Biol Ther; 2012 Aug; 12(8):1059-66. PubMed ID: 22681655
[TBL] [Abstract][Full Text] [Related]
32. No ethical bypass of moral status in stem cell research.
Brown M
Bioethics; 2013 Jan; 27(1):12-9. PubMed ID: 21726260
[TBL] [Abstract][Full Text] [Related]
33. Translating stem cell research: challenges at the research frontier.
Magnus D
J Law Med Ethics; 2010; 38(2):267-76. PubMed ID: 20579250
[TBL] [Abstract][Full Text] [Related]
34. Reprogramming of somatic cells.
Rajasingh J
Prog Mol Biol Transl Sci; 2012; 111():51-82. PubMed ID: 22917226
[TBL] [Abstract][Full Text] [Related]
35. Prospects for pluripotent stem cell therapies: into the clinic and back to the bench.
Grabel L
J Cell Biochem; 2012 Feb; 113(2):381-7. PubMed ID: 21928325
[TBL] [Abstract][Full Text] [Related]
36. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems.
Hwang DY; Kim DS; Kim DW
J Cell Biochem; 2010 Feb; 109(2):292-301. PubMed ID: 20014069
[TBL] [Abstract][Full Text] [Related]
37. iPS cell technology-based research for the treatment of diabetic nephropathy.
Osafune K
Semin Nephrol; 2012 Sep; 32(5):479-85. PubMed ID: 23062989
[TBL] [Abstract][Full Text] [Related]
38. Adhering to Ethical Benchmarks in Neurology Clinical Trials Using iPSCs.
Akabayashi A; Nakazawa E; Jecker NS
Neurotherapeutics; 2020 Apr; 17(2):606-608. PubMed ID: 30924090
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.
Zhou W; Freed CR
Stem Cells; 2009 Nov; 27(11):2667-74. PubMed ID: 19697349
[TBL] [Abstract][Full Text] [Related]
40. Pluripotent stem cells as new drugs? The example of Parkinson's disease.
Preynat-Seauve O; Burkhard PR; Villard J; Zingg W; Ginovart N; Feki A; Dubois-Dauphin M; Hurst SA; Mauron A; Jaconi M; Krause KH
Int J Pharm; 2009 Nov; 381(2):113-21. PubMed ID: 19782880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
